US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL
- Written by PR Newswire
- Investigational new drug (IND) approval received by QBiotics, to initiate a Phase II clinical trial investigating tigilanol tiglate in the treatment of patients with Soft Tissue Sarcoma (STS)
- The open label trial will evaluate efficacy and dose ranging in patients with advanced or metastatic STS
- Global Data estimates that there were 124,573 new...
